Abstract:PURPOSE OF REVIEW: The ability to generate pigs expressing a human complement regulatory protein (hCRP) and/or pigs in which the alpha1,3-galactosyltransferase gene has been knocked out (GT-KO) has largely overcome the barrier of hyperacute rejection of a pig organ transplanted into a primate. However, acute humoral xenograft rejection (AHXR), presenting as microvascular thrombosis and/or consumptive coagulopathy, remains a major hurdle to successful xenotransplantation. This review summarizes recent studies of the coagulation problems associated with xenotransplantation, and discusses potential strategies to overcome them.RECENT PROGRESS: Organ transplantation into nonhuman primates from GT-KO pigs that express a hCRP are not susceptible to hyperacute rejection. Nevertheless, most recipients of GT-KO and/or hCRP transgenic pig organs develop a consumptive coagulopathy, even when the graft remains functioning. This is associated with platelet aggregation, thrombocytopenia, anemia, and a tendency to bleed. Whilst this may reflect an ongoing immune response against the graft, (as exposure to anti-nonGal antibodies in vitro induces procoagulant changes in porcine ECs, even in the absence of complement), histological examination of the graft often shows only minimal features of immune injury, unlike grafts undergoing typical AHXR. Importantly, recent in vitro studies have indicated that the coincubation of porcine endothelial cells (ECs) with human platelets activates the platelets to express tissue factor, independent of a humoral immune response. These observations suggest that the use of organs from GT-KO pigs that express a hCRP may not be sufficient to prevent the development of a coagulation disorder following xenotransplantation, even if complete immunological tolerance can be achieved.SUMMARY: Both thrombotic microangiopathy and systemic consumptive coagulopathy are increasingly recognized as barriers to successful xenotransplantation. The breeding of transgenic pigs with one or more human anticoagulant genes, such as CD39 or tissue factor pathway inhibitor, is anticipated to inhibit the procoagulant changes that take place on the graft ECs, and thus may prevent or reduce platelet activation that arises as a result of immune-mediated injury. The identification of the molecular mechanisms that develop between porcine ECs and human platelets may allow pharmacological approaches to be determined that inhibit the development of thrombotic microangiopathy and consumptive coagulopathy. Hopefully, further genetic modification of the organ-source pigs, combined with systemic drug therapy to the recipient, will prolong graft survival further.

Platelet aggregation and thrombosis in xenotransplantation between pigs and humans

The role of platelets in coagulation dysfunction in xenotransplantation, and therapeutic options

[Xenogeneic Antigens and Immune Response in Pig to Man Xenograft].

Sequence Alignment Analysis of Proteins Involved in Platelet-Endothelial Cell Interaction Identifies Molecular Incompatibilities Between Homo Sapiens and Sus Scrofa

Process in the Study of Immunology and Potential Risks of Xenotransplantation

Coagulation dysregulation as a barrier to xenotransplantation in the primate

Progress towards overcoming coagulopathy and hemostatic dysfunction associated with xenotransplantation

Molecular incompatibilities in hemostasis between swine and men--impact on xenografting

The current state of xenotransplantation

Studies on Coagulation Incompatibilities for Xenotransplantation

Altered expression of eNOS, prostacyclin synthase, prostaglandin G/H synthase, and thromboxane synthase in porcine aortic endothelial cells after exposure to human serum-relevance to xenotransplantation.

Humanized von Willebrand factor reduces platelet sequestration in ex vivo and in vivo xenotransplant models

Genetic modification of pigs as organ donors for xenotransplantation

Genetic engineering of pigs for xenotransplantation to overcome immune rejection and physiological incompatibilities: The first clinical steps

The Progress of Genetic-modified Pigs as Donors in Xenotransplantation

Xenotransplantation: current status and a perspective on the future

The respective relevance of sensitization to alloantigens and xenoantigens in pig organ xenotransplantation

Cloning of Porcine Platelet Receptor GPIbα and Comparison with Human GPIbα

The resurgent landscape of xenotransplantation of pig organs in nonhuman primates

A review of pig liver xenotransplantation: Current problems and recent progress

Silencing Porcine CMAH and GGTA1 Genes Significantly Reduces Xenogeneic Consumption of Human Platelets by Porcine Livers